Evaluations
Tumors
ADVERSE EVENTS, DISEASE PROGRESSION, SECONDARY, TUMORS
The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), time to treatment failure (TTF), response rate, and adverse events. Tumors were assessed every 8 weeks until disease progression, and objective responses were evaluated according to RECIST version 1.1 [